Merck Nears Acquisition of Cidara Therapeutics at Significant Premium

Merck is reportedly close to finalizing a deal to acquire Cidara Therapeutics, offering a premium over the biotechnology company’s current market value of about $3.3 billion. According to a report from the Financial Times, the agreement could be announced as early as Friday, assuming no last-minute complications arise. Sources familiar with the negotiations said Merck had been competing with another major pharmaceutical company up until late Thursday, but Cidara ultimately moved forward with Merck’s proposal.

Although the exact purchase price has not been disclosed, the deal is expected to consist of an upfront cash payment along with additional milestone-based payouts tied to future clinical achievements. Such structures are commonly used in the biotech sector, particularly when promising drug candidates are still in development.

Cidara Therapeutics declined to comment on the report, and Merck has not yet issued an official response. The potential acquisition comes at a pivotal moment for Cidara, which recently received breakthrough therapy designation from the U.S. Food and Drug Administration for its investigational drug CD388. The treatment is designed to prevent influenza A and B in individuals at high risk of severe illness, a population with significant unmet medical needs. The FDA’s breakthrough designation is intended to accelerate the development and review of innovative therapies that could offer substantial clinical benefits.

Industry analysts note that Merck’s interest in Cidara underscores its strategy to strengthen its infectious disease pipeline and expand its portfolio of next-generation antiviral treatments. If finalized, the acquisition would position Merck to capitalize on growing market demand for advanced flu prevention options, especially following heightened global awareness of respiratory viruses in recent years.

The reported deal highlights the increasing competition among pharmaceutical companies to secure cutting-edge biotech assets with strong clinical potential, reinforcing the value of innovative drug platforms in today’s healthcare landscape.